Genscript Biotech Corporation
HKEX:1548.HK
12.04 (HKD) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 839.529 | 625.698 | 490.096 | 390.846 | 273.354 | 231.017 | 152.649 | 114.735 | 86.709 | 69.994 | 60.104 |
| Cost of Revenue
| 429.976 | 321.615 | 207.578 | 134.953 | 93.064 | 72.478 | 48.058 | 38.506 | 29.631 | 25.896 | 21.97 |
| Gross Profit
| 409.553 | 304.083 | 282.518 | 255.893 | 180.29 | 158.539 | 104.591 | 76.229 | 57.078 | 44.098 | 38.134 |
| Gross Profit Ratio
| 0.488 | 0.486 | 0.576 | 0.655 | 0.66 | 0.686 | 0.685 | 0.664 | 0.658 | 0.63 | 0.634 |
| Reseach & Development Expenses
| 432.827 | 390.096 | 358.401 | 263.401 | 186.022 | 74.076 | 18.055 | 9.467 | 7.109 | 5.589 | 6.064 |
| General & Administrative Expenses
| 213.441 | 182.462 | 134.508 | 90.341 | 55.256 | 40.582 | 22.039 | 30.429 | 28.535 | 21.446 | 16.377 |
| Selling & Marketing Expenses
| 174.298 | 168.349 | 167.969 | 107.341 | 70.358 | 38.771 | 24.908 | 20.867 | 17.642 | 15.538 | 12.813 |
| SG&A
| 387.739 | 352.101 | 303.405 | 197.038 | 125.614 | 79.353 | 46.947 | 51.296 | 46.177 | 36.984 | 29.19 |
| Other Expenses
| -27.03 | -21.473 | -12.16 | -94.314 | -0.384 | -0.036 | -7.347 | -0.06 | -0.29 | -0.327 | 0 |
| Operating Expenses
| 808.623 | 735.722 | 804.055 | 544.38 | 301.549 | 145.791 | 67.058 | 43.986 | 34.35 | 36.144 | 30.436 |
| Operating Income
| -415.791 | -438.114 | -379.288 | -204.546 | -131.346 | 5.11 | 39.589 | 24.933 | 10.901 | 7.114 | 8.59 |
| Operating Income Ratio
| -0.495 | -0.7 | -0.774 | -0.523 | -0.48 | 0.022 | 0.259 | 0.217 | 0.126 | 0.102 | 0.143 |
| Total Other Income Expenses Net
| 64.812 | 6.424 | -138.075 | -77.354 | 17.656 | 17.59 | -1.068 | 7.576 | 12.075 | 0.722 | -1.061 |
| Income Before Tax
| -350.979 | -431.69 | -517.363 | -281.9 | -113.69 | 22.7 | 38.521 | 32.509 | 22.976 | 7.836 | 7.529 |
| Income Before Tax Ratio
| -0.418 | -0.69 | -1.056 | -0.721 | -0.416 | 0.098 | 0.252 | 0.283 | 0.265 | 0.112 | 0.125 |
| Income Tax Expense
| 4.142 | 3.719 | 0.964 | 0.477 | 3.826 | 1.941 | 11.516 | 5.974 | 5.472 | 1.661 | 1.529 |
| Net Income
| -95.477 | -226.851 | -358.712 | -204.945 | -96.912 | 21.216 | 26.123 | 26.17 | 17.504 | 6.175 | 6 |
| Net Income Ratio
| -0.114 | -0.363 | -0.732 | -0.524 | -0.355 | 0.092 | 0.171 | 0.228 | 0.202 | 0.088 | 0.1 |
| EPS
| -0.045 | -0.11 | -0.18 | -0.11 | -0.052 | 0.012 | 0.015 | 0.016 | 0.015 | 0.005 | 0 |
| EPS Diluted
| -0.045 | -0.11 | -0.18 | -0.11 | -0.052 | 0.012 | 0.015 | 0.015 | 0.014 | 0.005 | 0 |
| EBITDA
| -278.868 | -389.035 | -341.569 | -174.708 | -112.362 | 17.444 | 46.204 | 29.975 | 15.586 | 11.817 | 13.084 |
| EBITDA Ratio
| -0.332 | -0.622 | -0.697 | -0.447 | -0.411 | 0.076 | 0.303 | 0.261 | 0.18 | 0.169 | 0.218 |